News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

|Articles|September 12, 2008

The effect of nausea and vomiting of pregnancy (nvp) on screening for depression

Coverage from the 28th annual meeting of the Society for Maternal-Fetal Medicine

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

Certolizumab pegol's FDA breakthrough designation, atogepant's LUNA results, deep implant removal guidance

Certolizumab pegol's FDA breakthrough designation, atogepant's LUNA results, deep implant removal guidance

ByJoshua Fitch, Senior Editor

September 14th 2026

Amber Watters, MD, on emergency preparedness and building a version program

Amber Watters, MD, on emergency preparedness and building a version program

ByAmber Watters, MD, MS

September 11th 2026

New tool translates pregnancy test research into individualized patient counseling resource

ByAlexandra C. Sundermann, MD, PhD

September 11th 2026

Kevin Ault, MD, on maternal immunization as a bridge to pediatric vaccination

ByKevin Ault, MD

September 11th 2026

Kevin Ault, MD, on the clinician's role in maternal COVID-19 vaccine counseling

Kevin Ault, MD, on the clinician's role in maternal COVID-19 vaccine counseling

ByKevin Ault, MD

September 9th 2026

Latest CME

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 5, 2026

Join Us at The Pathology Meeting in Las Vegas

In-Person + Virtual Event

Join Us at The Pathology Meeting in Las Vegas

October 4-5, 2026

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

Endometriosis as a systemic disease, with Hugh Taylor, MD

FDA accepts extended duration sNDA for MIUDELLA IUD

Certolizumab pegol's FDA breakthrough designation, atogepant's LUNA results, deep implant removal guidance

Society of Family Planning issues first guidance on deep and nonpalpable contraceptive implant removal

Phase 3 LUNA study: atogepant reduces menstrual migraine days vs. placebo